

# Joyce H S You

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5154636/publications.pdf>

Version: 2024-02-01

126  
papers

2,879  
citations

236925

25  
h-index

189892

50  
g-index

129  
all docs

129  
docs citations

129  
times ranked

3398  
citing authors

#	ARTICLE	IF	CITATIONS
1	The pharmacotherapeutic management of pulmonary tuberculosis: an update of the state-of-the-art. Expert Opinion on Pharmacotherapy, 2022, 23, 139-148.	1.8	1
2	Telemonitoring for patients with inflammatory bowel disease amid the COVID-19 pandemicâ€”A cost-effectiveness analysis. PLoS ONE, 2022, 17, e0266464.	2.5	2
3	Cost-effectiveness of internet-supported cognitive behavioral therapy for university students with anxiety symptoms: A Markov-model analysis. PLoS ONE, 2022, 17, e0268061.	2.5	6
4	Information technology-based versus face-to-face cognitive-behavioural therapy for anxiety and depression: A systematic review and meta-analysis. Journal of Affective Disorders, 2022, 310, 429-440.	4.1	3
5	A Systematic Review on Cost-effectiveness Analyses of Therapeutic Drug Monitoring for Patients with Inflammatory Bowel Disease: From Immunosuppressive to Anti-TNF Therapy. Inflammatory Bowel Diseases, 2021, 27, 275-282.	1.9	19
6	Impact of COVID-19 infection control measures on influenza-related outcomes in Hong Kong. Pathogens and Global Health, 2021, 115, 93-99.	2.3	2
7	Proactive therapeutic drug monitoring of adalimumab for pediatric Crohn's disease patients: A cost-effectiveness analysis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2397-2407.	2.8	10
8	EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong â€” A cost-effectiveness analysis. PLoS ONE, 2021, 16, e0247860.	2.5	7
9	Cost-effectiveness of a Telemonitoring Program for Patients With Heart Failure During the COVID-19 Pandemic in Hong Kong: Model Development and Data Analysis. Journal of Medical Internet Research, 2021, 23, e26516.	4.3	10
10	A systematic review of pharmacoeconomic evaluations on oral diarylquinoline-based treatment for drug-resistant tuberculosis: from high to low burden countries. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 897-910.	1.4	2
11	Cost-effectiveness of video-observed therapy for ambulatory management of active tuberculosis during the COVID-19 pandemic in a high-income country. International Journal of Infectious Diseases, 2021, 113, 271-278.	3.3	15
12	Cost-effectiveness analysis of fecal microbiota transplantation for recurrent <i>Clostridium difficile</i> infection in patients with inflammatory bowel disease. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1515-1523.	2.8	17
13	Telemonitoring Versus Usual Care for Elderly Patients With Heart Failure Discharged From the Hospital in the United States: Cost-Effectiveness Analysis. JMIR MHealth and UHealth, 2020, 8, e17846.	3.7	14
14	Standing orders program of pneumococcal vaccination for hospitalized elderly patients in Hong Kong: A cost-effectiveness analysis. American Journal of Infection Control, 2019, 47, 1302-1308.	2.3	4
15	Economic Analysis of Herpes Zoster in a Hospital Setting in Hong Kong. Acta Dermato-Venereologica, 2019, 99, 616-617.	1.3	2
16	Potential cost-effectiveness of wearable cardioverter-defibrillator for patients with implantable cardioverter-defibrillator explant in a high-income city of China. Journal of Cardiovascular Electrophysiology, 2019, 30, 2387-2396.	1.7	5
17	Noneffectiveness of electroacupuncture for comorbid generalized anxiety disorder and irritable bowel syndrome. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1736-1742.	2.8	8
18	Health Economic Analysis of Rivaroxaban and Warfarin for Venous Thromboembolism Management in Chinese Patients. Cardiovascular Drugs and Therapy, 2019, 33, 331-337.	2.6	2

#	ARTICLE	IF	CITATIONS
19	Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China. <i>International Journal of Infectious Diseases</i> , 2019, 78, 44-49.	3.3	13
20	Optimal gender-specific age for cost-effective vaccination with adjuvanted herpes zoster subunit vaccine in Chinese adults. <i>PLoS ONE</i> , 2019, 14, e0210005.	2.5	7
21	The Cost-Effectiveness of Digital Health Interventions on the Management of Cardiovascular Diseases: Systematic Review. <i>Journal of Medical Internet Research</i> , 2019, 21, e13166.	4.3	135
22	Antibiotic management of acute pharyngitis in primary care. <i>Hong Kong Medical Journal</i> , 2019, 25, 58-63.	0.1	1
23	Surveillance-guided selective digestive decontamination of carbapenem-resistant Enterobacteriaceae in the intensive care unit: A cost-effectiveness analysis. <i>American Journal of Infection Control</i> , 2018, 46, 291-296.	2.3	10
24	Influenza vaccine coverage and predictive factors associated with influenza vaccine uptake among pediatric patients. <i>American Journal of Infection Control</i> , 2018, 46, 1278-1283.	2.3	4
25	Potential cost-effectiveness of adjuvanted herpes zoster subunit vaccine for older adults in Hong Kong. <i>Vaccine</i> , 2018, 36, 4610-4620.	3.8	10
26	Cost-effectiveness analysis of ribotype-guided fecal microbiota transplantation in Chinese patients with severe <i>Clostridium difficile</i> infection. <i>PLoS ONE</i> , 2018, 13, e0201539.	2.5	10
27	Economic Outcomes of Influenza in Hospitalized Elderly with and without ICU Admission. <i>Antiviral Therapy</i> , 2017, 22, 173-177.	1.0	6
28	CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 39-49.	2.6	27
29	Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome. <i>Clinical Cardiology</i> , 2017, 40, 789-796.	1.8	5
30	Disease Burden, Characteristics, and Outcomes of Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infection in Hong Kong. <i>Asia-Pacific Journal of Public Health</i> , 2017, 29, 451-461.	1.0	14
31	Potential clinical and economic outcomes of active beta-D-glucan surveillance with preemptive therapy for invasive candidiasis at intensive care units: a decision model analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 187-194.	2.9	7
32	Cost-effectiveness of molecular point-of-care testing for influenza viruses in elderly patients at ambulatory care setting. <i>PLoS ONE</i> , 2017, 12, e0182091.	2.5	23
33	Potential Cost-Effectiveness of an Influenza Vaccination Program Offering Microneedle Patch for Vaccine Delivery in Children. <i>PLoS ONE</i> , 2016, 11, e0169030.	2.5	16
34	Active surveillance of carbapenem-resistant Enterobacteriaceae in intensive care units: Is it cost-effective in a nonendemic region?. <i>American Journal of Infection Control</i> , 2016, 44, 394-399.	2.3	31
35	Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome. <i>Pharmacogenomics</i> , 2016, 17, 701-713.	1.3	28
36	Cost-effectiveness of an influenza vaccination program offering intramuscular and intradermal vaccines versus intramuscular vaccine alone for elderly. <i>Vaccine</i> , 2016, 34, 2469-2476.	3.8	10

#	ARTICLE	IF	CITATIONS
37	Cost-effectiveness of culture-guided antimicrobial prophylaxis for the prevention of infections after prostate biopsy. <i>International Journal of Infectious Diseases</i> , 2016, 43, 7-12.	3.3	16
38	Universal Clopidogrel Versus Cyp2c19-Guided Antiplatelet Therapy In Patients With Acute Coronary Syndrome - A Cost-Effectiveness Analysis. <i>Value in Health</i> , 2015, 18, A19.	0.3	0
39	Cost-Effectiveness Evaluation Of Genotype-Guided Antiplatelet Therapy Versus Universal New Antiplatelet Therapy In Patients With Acute Coronary Syndrome. <i>Value in Health</i> , 2015, 18, A20.	0.3	0
40	CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 609-617.	1.5	14
41	Review of pharmaco-economic evaluation of genotype-guided antiplatelet therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 771-779.	1.8	21
42	Antimicrobial stewardship programs – cost-minimizing or cost-effective?. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 155-157.	1.8	9
43	Cost-effectiveness analysis of the Xpert MTB/RIF assay for rapid diagnosis of suspected tuberculosis in an intermediate burden area. <i>Journal of Infection</i> , 2015, 70, 409-414.	3.3	17
44	Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong – A decision analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 564-571.	3.3	37
45	Characteristics and outcomes of <i>Klebsiella pneumoniae</i> bacteraemia in Hong Kong. <i>Infectious Diseases</i> , 2015, 47, 283-288.	2.8	15
46	Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis. <i>Pharmacogenomics</i> , 2015, 16, 1089-1100.	1.3	13
47	Early supplemented low-protein diet restriction for chronic kidney disease patients in Taiwan – A cost-effectiveness analysis. <i>Clinical Nephrology</i> , 2015, 84 (2015), 189-196.	0.7	7
48	Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong. <i>BMC Infectious Diseases</i> , 2014, 14, 618.	2.9	37
49	Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 6-14.	1.5	26
50	Novel Oral Anticoagulants Versus Warfarin Therapy at Various Levels of Anticoagulation Control in Atrial Fibrillation – A Cost-Effectiveness Analysis. <i>Journal of General Internal Medicine</i> , 2014, 29, 438-446.	2.6	45
51	Early Versus Late Ketoanalog Supplementations In Patients With Chronic Kidney Disease In Taiwan – A Cost-Effectiveness Analysis. <i>Value in Health</i> , 2014, 17, A470.	0.3	0
52	Xpert Mtb/Rif Assay for Rapid Diagnosis in Patients with Suspected Tuberculosis in Hong Kong - a Cost-Effectiveness Analysis. <i>Value in Health</i> , 2014, 17, A678.	0.3	0
53	Quadrivalent Influenza Vaccine in Hong Kong- a Cost-Effectiveness Analysis. <i>Value in Health</i> , 2014, 17, A678.	0.3	1
54	Cost-effectiveness analysis of varicella vaccine as post-exposure prophylaxis in Hong Kong. <i>Scandinavian Journal of Infectious Diseases</i> , 2014, 46, 27-33.	1.5	10

#	ARTICLE	IF	CITATIONS
55	Prevention of gram-positive infections in peritoneal dialysis patients in Hong Kong: A cost-effectiveness analysis. <i>American Journal of Infection Control</i> , 2014, 42, 412-416.	2.3	15
56	Varicella Vaccine as Post-Exposure Prophylaxis – a Cost-Effectiveness Analysis. <i>Value in Health</i> , 2013, 16, A357.	0.3	0
57	Novel Oral Anticoagulants Versus Warfarin – A Business Case Analysis. <i>Value in Health</i> , 2013, 16, A528.	0.3	0
58	Impact Of Vaccination Coverage On Cost-Effectiveness Of Influenza Vaccine At Preventing Hospitalization. <i>Value in Health</i> , 2013, 16, A91-A92.	0.3	0
59	Prevention of Gram-Positive Infections in Peritoneal Dialysis Patients – A Cost-Effectiveness Analysis. <i>Value in Health</i> , 2013, 16, A358.	0.3	0
60	Cost-effectiveness of new oral anticoagulants for patients with atrial fibrillation – a decision analysis. <i>Value in Health</i> , 2013, 16, A285-A286.	0.3	1
61	Isoflavones in Treating Watchful Waiting Benign Prostate Hyperplasia: A Double-Blinded, Randomized Controlled Trial. <i>Journal of Alternative and Complementary Medicine</i> , 2012, 18, 54-60.	2.1	23
62	Active Surveillance and Decolonization of Methicillin-Resistant <i>Staphylococcus aureus</i> on Admission to Neonatal Intensive Care Units in Hong Kong: A Cost-Effectiveness Analysis. <i>Infection Control and Hospital Epidemiology</i> , 2012, 33, 1024-1030.	1.8	20
63	Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation. <i>PLoS ONE</i> , 2012, 7, e39640.	2.5	58
64	A Cost-Effectiveness Analysis of “Test” versus “Treat” Patients Hospitalized with Suspected Influenza in Hong Kong. <i>PLoS ONE</i> , 2012, 7, e33123.	2.5	21
65	New target concentrations for vancomycin in Hong Kong. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 83-84.	2.5	1
66	Pharmacoeconomic evaluation of warfarin pharmacogenomics. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 435-441.	1.8	26
67	Abstracts 40th Annual Meeting of the American College of Clinical Pharmacology September 11-13, 2011 Chicago, Illinois. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 1326-1369.	2.0	1
68	Anticoagulation: improve care quality or use new alternatives?. <i>Lancet, The</i> , 2011, 377, 464-465.	13.7	4
69	Complicated infections with methicillin-resistant <i>Staphylococcus aureus</i> in Hong Kong. <i>Journal of Hospital Infection</i> , 2011, 78, 71-72.	2.9	5
70	Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 113-118.	2.1	38
71	Public perception on the role of community pharmacists in self-medication and self-care in Hong Kong. <i>BMC Clinical Pharmacology</i> , 2011, 11, 19.	2.5	55
72	Patient self-management and pharmacist-led patient self-management in Hong Kong: A focus group study from different healthcare professionals' perspectives. <i>BMC Health Services Research</i> , 2011, 11, 121.	2.2	36

#	ARTICLE	IF	CITATIONS
73	Acinetobacter baumannii bacteraemia in Hong Kong. Journal of Hospital Infection, 2010, 75, 81.	2.9	2
74	Simultaneous measurement of S-warfarin, R-warfarin, S-7-hydroxywarfarin and R-7-hydroxywarfarin in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2010, 52, 305-310.	2.8	56
75	POLYPHARMACY AND INAPPROPRIATE PRESCRIBING IN ELDERLY HONG KONG CHINESE PATIENTS. Journal of the American Geriatrics Society, 2010, 58, 203-205.	2.6	16
76	CYP2C9*1B Promoter Polymorphisms, in Linkage with CYP2C19*2, Affect Phenytoin Autoinduction of Clearance and Maintenance Dose. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 599-611.	2.5	50
77	Effects of Concomitant Therapy with Diltiazem on the Lipid Responses to Simvastatin in Chinese Subjects. Journal of Clinical Pharmacology, 2010, 50, 1151-1158.	2.0	8
78	PIH17 COST-EFFECTIVENESS ANALYSIS OF FOUR EMBRYO TRANSFER STRATEGIES. Value in Health, 2010, 13, A183.	0.3	0
79	Do medical students agree with pharmacist-led patient self-management in Hong Kong?. Medical Teacher, 2010, 32, 1011-1011.	1.8	1
80	Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities. Journal of Epidemiology and Community Health, 2009, 63, 906-911.	3.7	24
81	Potential Clinical and Economic Outcomes of CYP2C9 and VKORC1 Genotype-Guided Dosing in Patients Starting Warfarin Therapy. Clinical Pharmacology and Therapeutics, 2009, 86, 540-547.	4.7	63
82	Uterine artery embolization, hysterectomy, or myomectomy for symptomatic uterine fibroids: a cost-utility analysis. Fertility and Sterility, 2009, 91, 580-588.	1.0	19
83	Bacteraemia with extended-spectrum $\beta$ -lactamases-producing Escherichia coli in Hong Kong. International Journal of Antimicrobial Agents, 2009, 34, 611-612.	2.5	3
84	PIN26 CLINICAL AND ECONOMIC IMPACTS OF BACTEREMIA CAUSED BY EXTENDED-SPECTRUM BETA-LACTAMASES PRODUCING ESCHERICHIA COLI IN HONG KONG. Value in Health, 2009, 12, A422.	0.3	0
85	PIN59 POTENTIAL ECONOMIC IMPACT OF OUTPATIENT CARBAPENEM TREATMENT FOR BACTERAEMIA CAUSED BY ESBL-PRODUCING BACTERIA IN HONG KONG-A DECISION ANALYSIS. Value in Health, 2009, 12, A428.	0.3	0
86	Public Knowledge, Attitudes and Behavior on Antibiotic Use: A Telephone Survey in Hong Kong. Infection, 2008, 36, 153-157.	4.7	140
87	ECONOMIC BURDEN OF INFORMAL CAREGIVERS FOR ELDERLY CHINESE IN HONG KONG. Journal of the American Geriatrics Society, 2008, 56, 1577-1578.	2.6	6
88	Are $\beta$ -lactams related to higher morbidity and mortality in urinary tract infections caused by extended-spectrum $\beta$ -lactamase-producing Escherichia coli?. Journal of Hospital Infection, 2008, 68, 181-183.	2.9	1
89	Meticillin-resistant Staphylococcus aureus bacteraemia in Hong Kong. Journal of Hospital Infection, 2008, 70, 379-381.	2.9	9
90	Pharmacoeconomics of entecavir treatment for chronic hepatitis B. Expert Opinion on Pharmacotherapy, 2008, 9, 2673-2681.	1.8	7

#	ARTICLE	IF	CITATIONS
91	Any effect of CYP2C9 variants on warfarin clearance in Chinese patients?. Thrombosis and Haemostasis, 2007, 97, 866-868.	3.4	2
92	Effect of an antimicrobial stewardship programme on the use of carbapenems in a Hong Kong teaching hospital: a pilot study. Journal of Hospital Infection, 2007, 65, 378-379.	2.9	3
93	Linezolid versus Vancomycin for Prosthetic Joint Infections: a Cost Analysis. Infection, 2007, 35, 265-270.	4.7	8
94	Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients - a cost analysis. International Journal of Clinical Pharmacology and Therapeutics, 2007, 45, 264-270.	0.6	8
95	Clinical and economic analyses of antimicrobial therapy in fever wards of a Hong Kong teaching hospital. International Journal of Clinical Pharmacology and Therapeutics, 2007, 45, 654-658.	0.6	2
96	Cost-effectiveness of Helicobacter pylori test and treatment for patients with typical reflux symptoms in a population with a high prevalence of H. pylori infection: A Markov model analysis. Scandinavian Journal of Gastroenterology, 2006, 41, 21-29.	1.5	12
97	The all-powerful and 'happy' drug: the use of steroids among primary care doctors in Hong Kong. Journal of Clinical Pharmacy and Therapeutics, 2006, 31, 173-178.	1.5	0
98	Management of Chinese patients on warfarin therapy in two models of anticoagulation service ? a prospective randomized trial. British Journal of Clinical Pharmacology, 2006, 62, 601-609.	2.4	55
99	A cost-utility analysis of hysterectomy, endometrial resection and ablation and medical therapy for menorrhagia. Human Reproduction, 2006, 21, 1878-1883.	0.9	33
100	The Cost-Effectiveness of an Outreach Clinical Model in the Management and Prevention of Gonorrhoea and Chlamydia Among Chinese Female Sex Workers in Hong Kong. Sexually Transmitted Diseases, 2006, 33, 220-227.	1.7	6
101	Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenetics and Genomics, 2005, 15, 687-691.	1.5	155
102	Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?. British Journal of Clinical Pharmacology, 2005, 59, 582-587.	2.4	123
103	Factors Affecting the Maintenance Stable Warfarin Dosage in Hong Kong Chinese Patients. Journal of Thrombosis and Thrombolysis, 2005, 20, 33-38.	2.1	25
104	Assessing adherence to statin therapy using patient report, pill count, and an electronic monitoring device. American Journal of Health-System Pharmacy, 2005, 62, 411-415.	1.0	15
105	Expectant, medical or surgical treatment for spontaneous abortion in first trimester of pregnancy: a cost analysis. Human Reproduction, 2005, 20, 2873-2878.	0.9	60
106	PMH30 FACTORS AFFECTING COST OF SCHIZOPHRENIA TREATMENT WITH ATYPICAL ANTIPSYCHOTIC AGENTS. Value in Health, 2005, 8, A205.	0.3	0
107	The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis. Thrombosis and Haemostasis, 2004, 92, 590-597.	3.4	55
108	Association between adherence to statin therapy and lipid control in Hong Kong Chinese patients at high risk of coronary heart disease. British Journal of Clinical Pharmacology, 2004, 58, 528-535.	2.4	42



#	ARTICLE	IF	CITATIONS
109	PCV4 VARIABLE PATIENT COMPLIANCE WITH STATINS AND ASSOCIATED LIPID CONTROL AMONG CHINESE PATIENTS WITH HIGH RISK FOR CORONARY HEART DISEASE. <i>Value in Health</i> , 2004, 7, 318-319.	0.3	0
110	PGI9 IS HELICOBACTER PYLORI $\alpha$ -TEST AND TREAT $\alpha$ -A COSTEFFECTIVE MANAGEMENT APPROACH FOR PATIENTS WITH TYPICAL REFLUX SYMPTOMS IN A POPULATION WITH A HIGH PREVALENCE OF H. PYLORI INFECTION. <i>Value in Health</i> , 2004, 7, 756.	0.3	0
111	Low $\alpha$ -dose or standard $\alpha$ -dose proton pump inhibitors for maintenance therapy of gastro $\alpha$ -esophageal reflux disease: a cost $\alpha$ -effectiveness analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 785-792.	3.7	15
112	Economic analysis of celecoxib versus diclofenac plus omeprazole for the treatment of arthritis in patients at risk of ulcer disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 217-222.	3.7	10
113	Cost-effectiveness analysis of high-dose omeprazole infusion as adjuvant therapy to endoscopic treatment of bleeding peptic ulcer. <i>Gastrointestinal Endoscopy</i> , 2003, 57, 160-164.	1.0	61
114	PCV69 THE COST-EFFECTIVENESS OF CYP2C9 GENOTYPING IN MANAGEMENT OF WARFARIN THERAPY-A DECISION TREE ANALYSIS. <i>Value in Health</i> , 2003, 6, 669-670.	0.3	0
115	PAR IO: A COST ANALYSIS OF CELECOXIB VERSUS DICLOFENAC PLUS OMEPRAZOLE FOR THE TREATMENT OF ARTHRITIS IN A GROUP OF HIGH-RISK CHINESE PATIENTS. <i>Value in Health</i> , 2003, 6, 223-224.	0.3	0
116	Outcomes of long-term warfarin therapy under two ambulatory care models in Hong Kong. <i>American Journal of Health-System Pharmacy</i> , 2003, 60, 1692-1692.	1.0	1
117	Medication education for non-English-speaking patients. <i>American Journal of Health-System Pharmacy</i> , 2003, 60, 1692-1694.	1.0	3
118	Impact of guidelines on vancomycin use at a Hong Kong teaching hospital. <i>American Journal of Health-System Pharmacy</i> , 2003, 60, 949-950.	1.0	3
119	Cost-effectiveness of two models of management for patients on chronic warfarin therapy $\alpha$ - a Markov model analysis. <i>Thrombosis and Haemostasis</i> , 2003, 90, 1106-1111.	3.4	14
120	PCV24 COST-EFFECTIVENESS OF ANTICOAGULATION MANAGEMENT IN TWO MODELS OF CARE. <i>Value in Health</i> , 2002, 5, 487.	0.3	0
121	PGS4 LOW-DOSE PPI AND STANDARD-DOSE PPI COMPARED WITH H2RA FOR MAINTENANCE THERAPY OF GERD $\alpha$ -A COST-EFFECTIVENESS ANALYSIS USING MARKOV MODEL. <i>Value in Health</i> , 2002, 5, 501-502.	0.3	0
122	Antimicrobial treatment of community-acquired pneumonia in Hong Kong. <i>American Journal of Health-System Pharmacy</i> , 2002, 59, 1785-1786.	1.0	1
123	Arthritis treatment in Hong Kong - cost analysis of celecoxib versus conventional NSAIDs, with or without gastroprotective agents. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 2089-2096.	3.7	25
124	Vancomycin utilization at a teaching hospital in Hong Kong. <i>American Journal of Health-System Pharmacy</i> , 2001, 58, 2167-2169.	1.0	9
125	Economic analysis of four triple regimens for the treatment of Helicobacter pylori -related peptic ulcer disease in in-patient and out-patient settings in Hong Kong. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 1009-1015.	3.7	4
126	Effect of Intravenous Omeprazole on Recurrent Bleeding after Endoscopic Treatment of Bleeding Peptic Ulcers. <i>New England Journal of Medicine</i> , 2000, 343, 310-316.	27.0	666